Case
long-acting agents and a lower discount on pipeline assets. We daclizumab and Plegridy as
$502
assume: underappreciated assets that can move
1) -$7.78 in global Teclidera sales ... Global hemophilia sales of -$28 ($1.28 to Biogen). injectable segment and daclizumab,
4) -$115/sharear he pipeline. and even with Phil like efficacy, will
5) Unchanged spending from our base case ... Daclizumab 160 256 383 533 697
US 104 166 247 340 433
Ex-US 56 90 137 193 264
Fampyra (EU only